Evidence map›Paper›PMID 41414951›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2026

Risk Assessment in Cardiovascular-Kidney-Metabolic Syndrome: An Opportunity to Individualize Evidence-Based Therapy in CKD.

L Parker Gregg, Biykem Bozkurt, Sankar D Navaneethan

Abstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.Journal of the American Society of Nephrology : JASN · 2026
    Guideline
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

L Parker GreggSection of Nephrology, Department of Medicine, Selzman Institute for Kidney Health, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-5469-367
Biykem BozkurtCenter for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas.ORCID 0000-0002-6362-0253
Sankar D NavaneethanSection of Nephrology, Department of Medicine, Selzman Institute for Kidney Health, Baylor College of Medicine, Houston, Texas.

Funding

MENTORED PATIENT-ORIENTED RESEARCH TOWARDS OPTIMIZING CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASEK24HL161414 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Sankar Dass Navaneethan · 2022 to 2026
$588k
CSRD VA IK2 CX002368Department of Veterans Affairs Health Service Research & Development Service Investigator Initiated Grants IIR 19-069Houston VA Health Services Research & Development Center for Innovations grant CIN13-413NHLBI K24-HL161414-01ANHLBI NIH HHS K24 HL161414NHLBI NIH HHS K24-HL161414-01AVA Clinical Sciences Research & Development Career Development Award IK2CX002368
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiovascular-kidney-metabolic (CKM) syndromeCKD

Identifiers

PMID41414951
PMCPMC13668220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.